FIELD: chemical industry.
SUBSTANCE: invention relates to compounds of Formula
I
or pharmaceutically acceptable salts thereof, wherein X1 is a CR1 or N; X2 is a CR2; X3 represents CR3; R1, R2 and R3 are independently selected from H, F; X4 is N; X5 represents CH or N; X6 and X7 represent CH; Y1 and Y2 are CH; Z is O or NR, where R H or C1-C3 alkyl; Q is selected from the group having the structure , , where R4 selected from -CH=CH2, -C(CN)=CH2, -C≡CCH3 and R5 is selected from H and C1-C3 alkyl; R6b, R7a and R7b are H; R6a is H or C1-C3 alkyl; or if Z is nitrogen, then Z and R6a form a five- or six-membered heterocyclic ring; R8 is CH2OH; R9 is selected from the following structures: and , useful for the inhibition of Btk, as well as for the treatment of tumors and inflammatory disorders such as inflammation mediated by Btk.
EFFECT: treatment of tumors and inflammatory disorders, such as inflammation mediated by Btk.
27 cl, 127 ex, 3 tbl
Title | Year | Author | Number |
---|---|---|---|
PURINONE COMPOUNDS AS KINASE INHIBITORS | 2013 |
|
RU2655388C2 |
PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE | 2011 |
|
RU2617405C2 |
PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS FOR APPLICATION | 2012 |
|
RU2638552C2 |
COMPOUND 8-FLUOROPHTHALAZINE-1(2H)-ONE AS INHIBITORS OF BRUTON TYROSINE KINASE | 2012 |
|
RU2622391C2 |
THIAZOLOPYRIMIDINONES AS MODULATORS OF NMDA RECEPTOR ACTIVITY | 2014 |
|
RU2703273C2 |
SUBSTITUTED PYRAZOLONE COMPOUNDS AND METHODS OF USE | 2013 |
|
RU2650895C2 |
BICYCLIC PIPERAZINE COMPOUNDS | 2012 |
|
RU2628616C2 |
CHEMICAL COMPOUNDS | 2018 |
|
RU2800292C2 |
PEPTIDE MACROCYCLES AGAINST ACINETOBACTER BAUMANNII | 2016 |
|
RU2729609C2 |
BRUTON'S TYROSINE KINASE INHIBITORS | 2014 |
|
RU2618529C2 |
Authors
Dates
2018-03-07—Published
2014-12-04—Filed